Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AMLX |
---|---|---|
09:32 ET | 28670 | 3.235 |
09:34 ET | 14383 | 3.235 |
09:36 ET | 700 | 3.2335 |
09:38 ET | 1400 | 3.265 |
09:39 ET | 1668 | 3.2649 |
09:41 ET | 3330 | 3.2605 |
09:43 ET | 7729 | 3.245 |
09:45 ET | 1891 | 3.235 |
09:48 ET | 14743 | 3.23 |
09:50 ET | 992 | 3.23 |
09:52 ET | 1386 | 3.21 |
09:54 ET | 100 | 3.2001 |
09:56 ET | 20654 | 3.205 |
09:57 ET | 1689 | 3.215 |
09:59 ET | 2653 | 3.2011 |
10:01 ET | 5239 | 3.205 |
10:03 ET | 419 | 3.205 |
10:06 ET | 9400 | 3.2 |
10:08 ET | 960 | 3.195 |
10:10 ET | 2779 | 3.195 |
10:12 ET | 2793 | 3.2094 |
10:14 ET | 249 | 3.21 |
10:15 ET | 1500 | 3.2046 |
10:17 ET | 100 | 3.205 |
10:19 ET | 166 | 3.2088 |
10:21 ET | 300 | 3.205 |
10:24 ET | 8288 | 3.195 |
10:26 ET | 1719 | 3.205 |
10:28 ET | 530 | 3.2085 |
10:30 ET | 100 | 3.2088 |
10:33 ET | 5425 | 3.1812 |
10:35 ET | 200 | 3.1808 |
10:37 ET | 6501 | 3.17 |
10:39 ET | 926 | 3.1711 |
10:42 ET | 450 | 3.175 |
10:46 ET | 300 | 3.175 |
10:48 ET | 3800 | 3.175 |
10:50 ET | 2133 | 3.175 |
10:51 ET | 1400 | 3.165 |
10:53 ET | 2300 | 3.165 |
10:55 ET | 2299 | 3.165 |
10:57 ET | 1338 | 3.19 |
11:00 ET | 1069 | 3.185 |
11:04 ET | 200 | 3.185 |
11:06 ET | 400 | 3.1888 |
11:08 ET | 700 | 3.1841 |
11:09 ET | 6319 | 3.165 |
11:11 ET | 4400 | 3.175 |
11:13 ET | 2000 | 3.1746 |
11:15 ET | 400 | 3.175 |
11:18 ET | 400 | 3.175 |
11:22 ET | 6508 | 3.19 |
11:24 ET | 3017 | 3.2 |
11:26 ET | 2000 | 3.19 |
11:27 ET | 1400 | 3.1901 |
11:29 ET | 800 | 3.195 |
11:31 ET | 100 | 3.19 |
11:36 ET | 500 | 3.1907 |
11:38 ET | 1312 | 3.185 |
11:40 ET | 863 | 3.1899 |
11:42 ET | 3000 | 3.1803 |
11:45 ET | 1604 | 3.189 |
11:47 ET | 2077 | 3.185 |
11:51 ET | 1144 | 3.175 |
11:54 ET | 3712 | 3.185 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Amylyx Pharmaceuticals Inc | 217.9M | -1.3x | --- |
Organogenesis Holdings Inc | 373.9M | -23.8x | --- |
Amarin Corporation PLC | 239.7M | -7.1x | --- |
Ironwood Pharmaceuticals Inc | 648.5M | 96.6x | --- |
Sinovac Biotech Ltd | 639.9M | -4.9x | --- |
Coherus BioSciences Inc | 122.1M | -2.7x | --- |
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $217.9M |
---|---|
Revenue (TTM) | $298.8M |
Shares Outstanding | 68.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.45 |
Book Value | $6.40 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -59.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.